Skip to main content
OpenTrials
Completed

NCT Number: NCT06052462

A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

The main purpose of this study is to evaluate how much of the study drug (LY3556050), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 58 days including the screening period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

LabCorp CRU, Inc.

Madison, Wisconsin, 53704, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male participants who are overtly healthy as determined by medical evaluation
  • Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive
  • Males who agree to use highly effective or effective methods of contraception

Exclusion criteria

  • Have known allergies to LY3556050, related compounds, or any components of the formulation of LY3556050, or history of significant atopy
  • Have clinically significant abnormal BP and/or pulse rate as determined by the investigator
  • Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing

Treatment and study plan

[14C]-LY3556050

Drug

Administered orally

Primary outcomes

  1. Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose up to Day 21 post dose

    Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

  2. Fecal Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Time frame: Predose up to Day 21 post dose

    Fecal Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Curve Concentration Versus Time Curve From Time zero to Last Time Point (AUC[0-tlast]) of LY3556050 in Plasma

    Time frame: Predose up to Day 21 post dose

    PK: AUC(0-tlast) of LY3556050 in Plasma

  2. PK: AUC(0-tlast) of Total Radioactivity in Plasma and Blood

    Time frame: Predose up to Day 21 post dose

    PK: AUC(0-tlast) of Total Radioactivity in Plasma and Blood

  3. PK: Area Under the Curve Concentration Versus Time Curve From zero to Infinity (AUC [0-∞]) of LY3556050 in Plasma

    Time frame: Predose up to Day 21 post dose

    PK: AUC (0-∞) of LY3556050 in Plasma

  4. PK: AUC (0-∞) of Total Radioactivity in Plasma and Blood

    Time frame: Predose up to Day 21 post dose

    PK: AUC (0-∞) of Total Radioactivity in Plasma and Blood

  5. PK: Maximum Concentration (Cmax) of LY3556050 in Plasma

    Time frame: Predose up to Day 21 post dose

    PK: Cmax of LY3556050 in Plasma

  6. PK: Cmax of Total Radioactivity in Plasma and Blood

    Time frame: Predose up to Day 21 post dose

    PK: Cmax of Total Radioactivity in Plasma and Blood

  7. Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)

    Time frame: Predose up to Day 7 post dose

    Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable)

  8. Total Number of Metabolites of LY3556050

    Time frame: Predose up to Day 7 post dose

    Total Number of Metabolites of LY3556050

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

Disposition of [14C]-LY3556050 Following Oral Administration in Healthy Male Participants

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Sep 25, 2023
Registry last updated
Jan 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.